If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
1.60    -0.09 (-5.33%)
Bid:
1.51
Ask:
1.75
Spread: 0.24 (15.894%)
Market Cap: £32.10m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Business Update

18 Aug 2025 07:00

RNS Number : 6922V
Quadrise PLC
18 August 2025
 

Certain of the information contained within this announcement is deemed by the Company to constitute inside information as stipulated under The Market Abuse Regulation (EU 596/2014) pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

18 August 2025

 

Quadrise plc

("Quadrise", "QED" or the "Company")

 

Business Update

 

 

Quadrise plc (AIM: QED), the technology company focused on the decarbonisation of shipping and heavy industry through deployment of low emission fuels and biofuels, is pleased to provide an update covering progress on its key projects.

Marine

The bilateral agreements between MSC and Cargill, and Quadrise and Cargill (the "Agreements"), remain in near final form, as announced by the Company on 10 June 2025. The Company has not received any adverse feedback from the relevant counterparties, and their internal processes remain ongoing, albeit slower than anticipated. On entry into the Agreements, the trial equipment will be installed and commissioned at the MAC2 site in Antwerp, ahead of the commercial scale trials commencing in due course. However, the commercial scale trials are no longer expected to commence in Q3 2025, as previously expected, as a result of delays in entry of the Agreements.

In the meantime, the Company continues to build the marine business development pipeline aimed at accelerating the commercialisation of bioMSARTM and MSAR®.

Americas

The trials with Sparkle Power SA in Panama have concluded to the satisfaction of the onsite teams and the Company is now awaiting the official results from the engine manufacturer and the client, the conclusions of which will be announced by the Company following receipt. As previously announced, a confirmed successful trial will enable the Company to negotiate Fuel Supply Agreements and facilitate discussions with other regional power producers. The trials are also an important milestone for Quadrise, being the first test for the MSAR® and bioMSAR™ on MAN 4-stroke diesel engines, to confirm the potential to expand product applications.

Morocco

The Company continues to await final approval from the original equipment manufacturer ("OEM"), to progress the planned commercial trial with OCP. All trial equipment is in place pending OEM approval.

US Low Carbon Fuels

Production growth by Valkor in Utah has progressed slower than expected during 2025, and current levels of production have been insufficient to feed the development of mid-stream operations and marketing. Valkor expect this situation to be resolved shortly.

Quadrise and Valkor are currently negotiating a compensation payment to the Company for the deferral of payment of the initial licence fee due to the Company in the amount of USD$350,000 which was originally due in January 2025. A further update will be provided, as appropriate, in due course.

bioMSAR™ and bioMSAR™ Zero development

Quadrise continues to advance several additional joint development and commercial discussions and testing with potential partners and customers to seek to deliver cleaner fuels at a lower cost than alternatives.

Andy Morrison, Chair of Quadrise, commented:

"Whilst much is being done to prepare ourselves for the scale-up of our business, it is disappointing that we have not been able to progress our existing projects as quickly as we had expected. We remain committed to completing these projects, to demonstrating the significant value add to our clients that Quadrise technology can bring, and to being positioned to act quickly as and when further opportunities arise."

 

For further information please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Technology Officer

 

 

Nominated Adviser

Cavendish Capital Markets Limited

 

 

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

 

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs, Harry Davies-Ball (Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

 

 

+44 (0)20 3005 5000

 

Public & Investor Relations

 

 

Tavistock Communications (Financial PR & IR)

Simon Hudson

Nick Elwes

Ruairi Millar

 

+44 (0) 20 7920 3150

 

 BLUE Communications Limited (Marine & Trade PR)

 Rhys Thomas

 Sam Deacon

 

 

 

+44 (0)7595 227750

+44 (0)7527 558846

 

 

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to lower energy costs, pollution and greenhouse gas emissions today for the global power generation, shipping, industrial and oil industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X: @QuadrisePlc

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDKZGMRKRMGKZG
Date   Source Headline
2nd Aug 20247:00 amRNSIssue of Share Options and Director/PDMR Dealing
1st Aug 20247:00 amRNSValkor Project Update
10th Jul 20247:00 amRNSMarine Project Update
26th Jun 20247:00 amRNSExtended agreement with BTG Bioliquids for bioMSAR
29th May 20247:00 amRNSRepresentation Agreement Addendum & Warrants Grant
28th May 20247:00 amRNSOCP Commercial Framework Agreement
2nd May 20247:00 amRNSQuadrise-Vertoro JDA to sea-trial bioMSAR Zero
29th Apr 20247:00 amRNSMarine Project Update
19th Apr 20247:00 amRNSValkor Project Update
12th Apr 20244:58 pmRNSResults of Open Offer
22nd Mar 20243:10 pmRNSExtension of Open Offer Closing Date
20th Mar 20241:01 pmRNSInvestor Presentation
19th Mar 20247:00 amRNSPlacing Results, Open Offer & Posting of Circular
18th Mar 20244:55 pmRNSProposed Placing, Subscription and Open Offer
18th Mar 20244:53 pmRNSInterim Results
15th Feb 20247:00 amRNSAgreement with Euthenia & BTG Bioliquids
6th Feb 20247:00 amRNSMarine Project Update
6th Dec 20237:00 amRNSUpdate re bioMSARâ„¢ and bioMSARâ„¢ Zero Development
27th Nov 20235:46 pmRNSResult of AGM
27th Nov 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSMorocco Project Update
9th Nov 20237:00 amRNSPublication of 2023 Sustainability Report
31st Oct 202312:45 pmRNSMorocco Project Update
27th Oct 20234:20 pmRNSPosting of Annual Report & Notice of AGM
24th Oct 20239:33 amRNSChange of Nominated Adviser
2nd Oct 20237:30 amRNSDirectorate Change
2nd Oct 20237:00 amRNSFinal Results and Notice of AGM
12th Sep 20237:00 amRNSMorocco Project Update
29th Aug 20237:00 amRNSValkor Project Update
24th Aug 202312:29 pmRNSValkor Update
18th Aug 20233:46 pmRNSMorocco Update
4th Aug 20237:00 amRNSIssue of Share Options and Director/PDMR Dealing
1st Aug 20234:15 pmRNSDirector/PDMR Shareholding
28th Jul 20234:25 pmRNSDirector/PDMR Shareholding
25th Jul 20233:34 pmRNSResults of Open Offer
7th Jul 202312:00 pmRNSInvestor Presentation
7th Jul 202310:38 amRNSPlacing Results, Open Offer & Posting of Circular
7th Jul 20237:00 amRNSProposed Placing and Open Offer
22nd Jun 20237:00 amRNSMorocco Update
12th Jun 20237:00 amRNSValkor Site License & Supply Agreement
8th Jun 20237:00 amRNSJoint Development Agreement with BTG Bioliquids
26th May 20237:00 amRNSVertoro Joint Development Agreement Update
22nd May 20237:00 amRNSMorocco Update
16th May 20234:29 pmRNSReplacement: Business Update
16th May 20237:00 amRNSBusiness Update
25th Apr 20237:00 amRNSAppointment of Joint Broker
29th Mar 20237:00 amRNSInterim Results
28th Mar 20237:00 amRNSChange of Company Name
22nd Oct 20155:26 pmRNSDelisting of Quintain ordinary shares
15th Oct 20154:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.